Skip to main content

Table 1 Patient characteristics and their prognostic impact on overall survival

From: Effect of antiangiogenic-based treatment and systemic inflammatory factors on outcomes in patients with BRAF v600-mutated metastatic colorectal cancer: a real-world study in Spain

Characteristics N = 72 OS (months) HR (95% CI) p-valuea
Age, years
 Median 62.4
 Range 30–83
Sex, n (%)
 Male 33 (45.8) 9.4 1.317 (0.8–2.2) 0.308
 Female 39 (54.2) 12.8
ECOG PS, n (%)     
 0–1 52 (72.2) 11.9 0.632 (0.3–1.2) 0.161
 2–3 20 (27.8) 7.1
Tumor location, n (%)
 Right-sided 35 (48.6) 10.6 0.296
 Left-sided 22 (30.6) 11.3
 Rectum 15 (20.8) 13.1
Histological grade, n (%)
 Low grade (G1–2) 37 (51.4) 11.9 0.895 (0.5–1.7) 0.723
 High grade (G3) 23 (31.9) 11.1
 Unknown 12 (16.7)    
Mismatch repair proteins, n (%) n=33    
 Conserved 31 (93.1) 12.8 0.146 (0.1–0.8) 0.010
 Deficiency 2 (6.9) 4.9
Tumor presentation, n (%)
 Synchronous 50 (69.4) 12.4 0.903 (0.5–1.6) 0.730
 Metachronous 22 (30.6) 5.9
Primary tumor surgery, n (%)
 No 25 (34.7) 9.6 1.932 (1.1–3.4) 0.023
 Yes 47 (65.3) 11.9
Metastasectomy, n (%)
 No 57 (79.2) 9.6 2.307 (1.2–4.6) 0.011
 Yes 15 (20.8) 19.6
  1. CI Confidence interval, ECOG PS Eastern Cooperative Oncology Group performance status, G Grade, HR Hazard ratio, OS Overall survival
  2. aSignificant values are indicated in bold
\